Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8513MR)

This product GTTS-WQ8513MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Neuroblastoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8513MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5316MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ4666MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ3639MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ3957MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ566MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ13092MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ14212MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ6629MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DCDS0780A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW